Company intelligence / Profile preview

VIZO Specs

Ownership: Private
Development stage: Commercial

Overview

The company’s flagship product, VIZO Glasses™, is a wearable medical device with embedded technology designed to improve attention and executive function in individuals with ADHD or attention difficulties. The product has received regulatory approval from the Israeli Ministry of Health and holds a CE certificate. It is currently marketed in Israel. Clinical results are not detailed publicly but regulatory approvals suggest demonstrated efficacy.

Therapeutic areas: Psychiatry
Modalities: Device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Sparkles

Commercial

Indications: Attention deficit hyperactivity disorder

Beyond the preview

Go deeper on VIZO Specs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VIZO Specs.

Explore the full profile